肝细胞癌治疗中分子靶向药物在肝癌治疗中的地位课件.pptVIP

* * Bisphosphonates Overview * * Bisphosphonates Overview * * Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Background Aims: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC). Metronomic chemotherapy using tegafur/uracil (4:1 molar ratio), an oral fluoropyrimidine, has been shown to enhance the anti-tumor effect of anti-angiogenic agents in preclinical models. This phase II study evaluated the efficacy and safety of combining metronom